Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02871531
Other study ID # Extended criteria pneumaticPPV
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 2016
Est. completion date November 2023

Study information

Verified date August 2019
Source St. Michael's Hospital, Toronto
Contact Rajeev Muni, MD
Phone 416-867-7411
Email rajeev.muni@utoronto.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Objective: To compare outcomes of retinal detachment repair following pneumatic retinopexy (PnR) versus pars plana vitrectomy in terms of anatomical success, functional success and patient quality of life in patients with extended criteria.

Methods: A prospective, randomized, controlled trial will be conducted with 178 patients presenting at St. Michael's Hospital with primary retinal detachment (RD). Inclusion criteria include: a single or multiple retinal tears in detached retina between 7 and 5 o'clock being of any size and any distance apart from each other, including giant retinal tears with inferior aspect above 5 and 7 o'clock, RD with no identifiable tear but where suspected tear is between 7 and 5 o'clock, retinoschisis with RD if tears are located between 7 and 5 o'clock, mild proliferative vitreoretinopathy, none or mild vitreous hemorrhage. Patients will be excluded if there is a small retinal tear or multiple tears less than 30o apart between 8 and 4 o'clock in detached retina, retinal tear in detached retina between 5 and 7 o'clock, <18 years old, inability to read English, mental incapacity, previous history of RD, scleral buckle or vitrectomy in index eye, inability to maintain appropriate head posture at post-operative period and inability to visualize peripheral retinal due to media opacity. Patients will be randomly allocated into two groups: PnR + cryotherapy/laser or vitrectomy + cryotherapy/laser and the intervention will take place within 24 hours and 72 hours for attached and detached macula status, respectively. Patients will undergo a complete ophthalmological examination, including visual acuity and fundus assessment at baseline and at 3, 6 and 12 months after surgery. Visual acuity will also be measured at 1, 7 and 30 days after surgery. Global health related quality of life will be evaluated with the SF-36v2 questionnaire at baseline, 1 month, 1 and 2 years after intervention, while the VFG25 questionnaire will be applied at 3, 6, 12 and 24 months after surgery to measure vision related quality of life.


Recruitment information / eligibility

Status Recruiting
Enrollment 178
Est. completion date November 2023
Est. primary completion date November 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Single retinal tear or group of tears (any distance apart) in detached retina located between 7 and 5 o'clock.

- Retinal detachment with no identifiable tear but where suspected tear is located between 7-5 o'clock based on Lincoff rules

- Any size of retinal tear, including giant retinal tears, if the inferior aspect of it is above 5 and 7 o'clock

- Retinoschisis with retinal detachment if tears are located between 7 and 5 o'clock

- There may be mild proliferative vitreoretinopathy (unless there is a visible traction on the break)

- None or mild vitreous hemorrhage. Note: vitreous hemorrhage will be considered mild if it does not impair an adequate examination of the retinal periphery.

- In the opinion of the investigator, PnR is likely to achieve anatomical re-attachment of the retina

Exclusion Criteria:

- Group of tears <30o apart in detached retina if all located within 8-4 o'clock

- Single retinal tear smaller than 1 o'clock in detached retina between 8-4 o'clock

- Retinal tears below the 5 and 7 o'clock meridian in detached retina (note that additional tears in attached retina are acceptable)

- Inability to read English language

- Age <18 years

- Mental incapacity

- Previous vitrectomy or scleral buckle (index eye)

- Previous retinal detachment (index eye)

- Inability to maintain the strict post-operative posturing requirements of pneumatic retinopexy

- Inability to carry out detailed examination of the peripheral retina due to media opacity NOTE: Lens/posterior hyaloid status does not affect eligibility.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Pneumatic retinopexy

Vitrectomy


Locations

Country Name City State
Canada St. Michael's Hospital Eye Clinic Toronto Ontario
Canada Sunnybrook Health Sciences Centre Toronto

Sponsors (1)

Lead Sponsor Collaborator
St. Michael's Hospital, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual acuity (ETDRS) 12 months post intervention
Secondary Visual acuity (ETDRS) 3, 6 and 24 months post intervention
Secondary Visual acuity (Snellen) 1 week, 1, 3, 6, 12 and 24 months post intervention
Secondary Subjective visual function (VFQ25) 3, 6, 12 and 24 months post intervention
Secondary Anatomical success (complete retinal re-attachment with no adjuvant surgical procedure) 3, 6, 12 and 24 months post intervention
Secondary Subjective health related quality of life (SF-36v2) baseline, 1 month, 12 and 24 months post intervention
Secondary Aniseikonia rates 12 and 24 months
Secondary Metamorphopsia rates 3, 12 and 24 months
Secondary Retinal displacement rate measured with fundus autofluorescence 3 and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04403750 - Combined Laser-surgical Technology of RRD Treatment N/A
Not yet recruiting NCT04520789 - Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencingvitreoretinopathy N/A
Recruiting NCT04571788 - Treating Rhegmatogenous Retinal Detachment by Foldable Capsular Buckle
Completed NCT02834559 - Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. Phase 3
Recruiting NCT01845571 - Retinal Detachment - Demographic and Clinical Survey
Completed NCT04891991 - Intravitreal Infliximab for Proliferative Vitreoretinopathy Phase 2
Completed NCT00757536 - Primary Vitrectomy With Endolaser or Encircling Band for Rhegmatogenous Retinal Detachment N/A
Active, not recruiting NCT00370201 - Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Phase 3
Completed NCT00345007 - Macular Function After Scleral Buckle N/A
Recruiting NCT05331664 - Dropless Pars Plana Vitrectomy Study Phase 4
Completed NCT02841306 - Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment Phase 1
Not yet recruiting NCT02185469 - Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment N/A
Not yet recruiting NCT01647373 - Axial Length Change in Eyes Treated by Silicone Sponge Scleral Buckling N/A
Completed NCT01068379 - Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation Phase 3
Not yet recruiting NCT06425419 - The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy Phase 1
Recruiting NCT06056596 - Lamivudine and Plasma Markers of Inflammation in Retinal Detachment Early Phase 1
Completed NCT01343134 - Anatomical and Functional Macular Changes in Retinal Detachment N/A
Recruiting NCT05588037 - Combined Vitrectomy and Femtosecond Laser-assisted Cataract Surgery N/A
Completed NCT03542162 - Healaflow Patch for the Treatment of Rhegmatogenous Retinal Detachment N/A
Recruiting NCT05660447 - A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR Phase 2/Phase 3